Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
Phase 4 N=432 Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
Tobacco Use Cessation
Primary: Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco — 125; 85 participants — p=<0.0001
Phase 2 N=237 Efficacy of Varenicline for Smokeless Tobacco Use in India
Tobacco Use Disorder
Primary: 7-day Point Prevalence Smokeless Tobacco Abstinence Biochemically Confirmed With Urine Cotinine at the End of 12 Weeks of Treatment. — 30; 23 participants
N/A N=76 Varenicline for the Treatment of Smokeless Tobacco
Nicotine Dependence
Primary: 7-day Point Prevalence All Tobacco Abstinence — 21; 16 participants — p=0.126
Phase 2 N=332 Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
Tobacco Use Disorder
Primary: Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence) — 31; 17 percentage of randomized — p=0.04
N/A N=60 Smokeless Tobacco Cessation Intervention for Firefighters
Smokeless Tobacco Cessation
Primary: Number of First Responders Recruited Who Completed a Screening Assessment — 163 Participants
N/A N=1,236 A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco
Smoking · Smoking Cessation
Primary: Quit Attempts and Abstinence — 25.7; 30.8; 19.8; 25.6 percentage of participants
Phase 3 N=270 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Smokeless Tobacco Use
Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
Phase 4 N=250 Controlled Study of the Ability of a Smokefree Tobacco Product to Increase the Quit Rate Among Cigarette Smokers
Cigarette Smoking
Primary: Continuous Rate of Smoking Cessation by Self-report and Confirmed by Expired Air Carbon Monoxide Less or Equal Than 8 Ppm — 5; 2 participants
Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
Phase 1 N=58 Persistence-Targeted Smoking Cessation
Tobacco Use Disorder
Primary: 7-day Point Prevalence Abstinence — 4; 1 participants
Phase 2 N=391 Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
Tobacco Use Disorder
Primary: Product Effect on Complete Substitution for Smoking — 56; 56 participants
N/A N=67 Acceptability of Less Harmful Alternatives to Cigarettes
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs) — 7 participants
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
N/A N=1,094 Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Smoking Cessation
Primary: Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey — 13.0; 13.5 percentage of participants — p=0.865
Phase 3 N=463 Smoking Cessation for American Indians
Smoking Cessation
Primary: 7-Day Point Prevalence Abstinence From Smoking for 6 Months — 49; 26; 26; 15 Participants
N/A N=369 Cessation in Non-Daily Smokers
Smoking
Primary: Smoking Cessation, Continuous 6-month Abstinence — 13; 10 Participants — p=0.46
N/A N=359 Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
Smokeless Tobacco Use · Tobacco Dependence
Primary: Extent of Toxicity: Mean of Median Values of NNK+NNN in 7 Smokeless Tobacco Brands — 2.4; 2.25; 3.19; 5.51 ug/g
Phase 4 N=987 Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines
Smoking · Smoking Cessation
Primary: 7-Day Point Prevalence Abstinence From Smoking by Intervention — 43.3; 48.9; 42.3; 49.9 Percentage of participants not smoking — p=.076
N/A N=56 Engaging Patients in Tobacco Cessation Resources in Dental Settings
Smoking
Primary: Percentage of Smokers With Delivery of Brief Interventions and/or Referral to Treatment — 7; 36 Participants
N/A N=30 Quit or Switch: E-cigarette Study
Tobacco Use
Primary: Percentage of Participants Who Report Daily Use of E-cigarettes or NRT and no Cigarette Use
N/A N=109 Tobacco Dependence Treatment for Asian Americans
Tobacco Dependence
Primary: 12-month Abstinence — 21; 6 Participants — p=<0.01
N/A N=122 Smoking Cessation in Menthol Flavored Cigarette Smokers
Tobacco Use Disorder
Primary: Time to Lapse — 1.07; 2.55 days
Phase 4 N=642 Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)
Smoking, Tobacco
Primary: Number of Participants With Self-reported Past 7-day Smoking Abstinence — 12; 10; 12; 15 Participants
Phase 4 N=112 Smoking Cessation Treatment for Methadone Maintenance Patients
Smoking Cessation · Substance-Related Disorders
Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03
N/A N=154 Enhancing a High School Based Smoking Cessation Program
Nicotine Dependence
Primary: Abstinence Rates at the End of Treatment — 35.1; 24.3; 38.6; 36.1 percentage of participants not smoking
N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants